Zobrazeno 1 - 10
of 35
pro vyhledávání: '"R.K. Zeldin"'
Autor:
Paul Knöbl, Javier de la Rubia, Johanna A. Kremer Hovinga, Spero R. Cataland, Ara Metjian, Flora Peyvandi, Paul Coppo, Marie Scully, Debjit Biswas, R.K. Zeldin, Filip Callewaert, Hercules Investigators, Hilde De Winter, Katerina Pavenski
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a37198cd06aaddd794a11158bd78bdca
https://www.zora.uzh.ch/id/eprint/175165/
https://www.zora.uzh.ch/id/eprint/175165/
Autor:
Marie Scully, J. A. Kremer Hovinga, R.K. Zeldin, Filip Callewaert, Katerina Pavenski, Spero R. Cataland, J de la Rubia, P. Knoebl, H. De Winter, Paul Coppo, Flora Peyvandi, Ara Metjian
Publikováno v:
La Revue de Médecine Interne. 40:A76-A77
Introduction L’efficacite du caplacizumab dans le Purpura Thrombotique Thrombocytopenique acquis (PTTa) a ete demontree vs bras controle placebo, les deux bras conjointement a une association echanges plasmatiques et traitement immunosuppresseur, d
Autor:
Michael E. Weinblatt, Rieke Alten, Thomas Dörner, K Van Beneden, R.K. Zeldin, P Schoen, EJ Dombrecht, K De Beuf, Patrick Durez
Publikováno v:
Oral Presentations.
Background Vobarilizumab is a Nanobody® consisting of an anti-IL-6R domain and an anti-human serum albumin domain in development for treatment of RA. The efficacy and safety were assessed in a 24-week double-blind global phase 2b study in patients w
Autor:
P Schoen, Michael E. Weinblatt, R.K. Zeldin, EJ Dombrecht, K De Beuf, Thomas Dörner, K Van Beneden
Publikováno v:
Poster Presentations.
Background Vobarilizumab is a Nanobody® consisting of an anti-IL6 receptor domain and an anti-human serum albumin domain in development for treatment of RA. Objectives To assess the efficacy and safety of several dose regimens of vobarilizumab monot
Autor:
Marie Scully, J. A. Kremer Hovinga, Spero R. Cataland, Filip Callewaert, K De Beuf, H. De Winter, Flora Peyvandi, R.K. Zeldin, Paul Knöbl
Publikováno v:
Peyvandi, F; Scully, M; Kremer Hovinga, Johanna Anna; Knöbl, P; Cataland, S; De Beuf, K; Callewaert, F; De Winter, H; Zeldin, R K (2017). Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 15(7), pp. 1448-1452. Wiley-Blackwell 10.1111/jth.13716
BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a life-threatening autoimmune thrombotic microangiopathy. In spite of treatment with plasma exchange and immunosuppression, patients remain at risk for thrombotic complications, exacer
Autor:
D. Biswas, R.K. Zeldin, P. Knoebl, Flora Peyvandi, Katerina Pavenski, H. De Winter, Marie Scully, J. A. Kremer Hovinga, Spero R. Cataland, investigateurs de l’essai Hercules, Ara Metjian, Paul Coppo, J de la Rubia
Publikováno v:
La Revue de Médecine Interne. 39:A61-A62
Introduction Le caplacizumab est un nanocorps divalent inhibant l’adhesion plaquettaire par fixation au domaine A1 du facteur Willebrand. Nous avons evalue son efficacite et sa tolerance dans le traitement du purpura thrombotique thrombocytopenique
Autor:
S. Spangenthal, G. Mizutani, Michelle Henley, D. Cheung, R.K. Zeldin, C. Vogelmeier, S.Z. Güçlü, J.B. Galdiz, C. Verkindre, Tim Overend
Publikováno v:
Pulmonary pharmacologytherapeutics. 23(5)
NVA237 is a novel once-daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler. This randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and bronchodilator efficacy of two doses of NVA23
Publikováno v:
Pneumologie. 63
Publikováno v:
Journal of Allergy and Clinical Immunology. 97:429-429
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.